CU20170082A7 - Complejo de torio dirigido a tejido y método para su preparación - Google Patents
Complejo de torio dirigido a tejido y método para su preparaciónInfo
- Publication number
- CU20170082A7 CU20170082A7 CUP2017000082A CU20170082A CU20170082A7 CU 20170082 A7 CU20170082 A7 CU 20170082A7 CU P2017000082 A CUP2017000082 A CU P2017000082A CU 20170082 A CU20170082 A CU 20170082A CU 20170082 A7 CU20170082 A7 CU 20170082A7
- Authority
- CU
- Cuba
- Prior art keywords
- tissue
- chelator
- complex
- thorium
- targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<p>La invención provee un método para la formación de un complejo de torio dirigido a tejido, en donde dicho método comprende;<br /> a) formar un quelante octadentado que comprende cuatro porciones hidroxipiridinona (HOPO) sustituidas en la posicion N con un grupo C1-C3alquilo, y una porción de acoplamiento que termina en un grupo ácido carboxilico;<br /> b) acoplar dicho quelante octadentado a por lo menos un péptido o proteína de direccionamiento a<br /> tejido que comprende por lo menos una porción amina por medio de por lo menos un reactivo de acoplamiento de amida para generar así un quelante de direccionamiento a tejido; y<br /> c) poner en contacto dicho quelante de direccionamiento a tejido con una solución acuosa que comprende un ion de por lo menos un isótopo de torio emisor alfa.<br /> Un método de tratamiento de una enfermedad neoplásica o hiperplásica que comprende la<br /> administración de dicho complejo de torio dirigido a tejido, asi como también se proveen el complejo y formulaciones farmacéuticas correspondientes.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422512 | 2014-12-17 | ||
| PCT/EP2015/079773 WO2016096843A1 (en) | 2014-12-17 | 2015-12-15 | Radio-pharmaceutical complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170082A7 true CU20170082A7 (es) | 2017-10-05 |
| CU24493B1 CU24493B1 (es) | 2020-12-17 |
Family
ID=54884033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000082A CU24493B1 (es) | 2014-12-17 | 2015-12-15 | Complejo de torio dirigido a tejido |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20170340759A1 (es) |
| EP (1) | EP3233137A1 (es) |
| JP (2) | JP6821569B2 (es) |
| KR (1) | KR20170094223A (es) |
| CN (1) | CN107278155B (es) |
| AR (1) | AR103063A1 (es) |
| AU (2) | AU2015367722A1 (es) |
| BR (1) | BR112017012841A2 (es) |
| CA (1) | CA2970841A1 (es) |
| CL (1) | CL2017001592A1 (es) |
| CO (1) | CO2017005975A2 (es) |
| CR (1) | CR20170256A (es) |
| CU (1) | CU24493B1 (es) |
| DO (1) | DOP2017000143A (es) |
| EA (1) | EA201791350A9 (es) |
| EC (1) | ECSP17038089A (es) |
| IL (1) | IL252244B (es) |
| JO (1) | JOP20150319B1 (es) |
| MA (1) | MA41176A (es) |
| MX (1) | MX2017008093A (es) |
| MY (1) | MY194190A (es) |
| NI (1) | NI201700076A (es) |
| PE (2) | PE20230829A1 (es) |
| PH (1) | PH12017501125A1 (es) |
| SG (1) | SG11201704917XA (es) |
| TN (1) | TN2017000255A1 (es) |
| TW (1) | TWI654179B (es) |
| UA (1) | UA125369C2 (es) |
| UY (1) | UY36453A (es) |
| WO (1) | WO2016096843A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108778347A (zh) * | 2016-03-24 | 2018-11-09 | 拜耳制药股份公司 | 放射性药物配合物 |
| CN109689115A (zh) * | 2016-06-10 | 2019-04-26 | 拜耳制药股份公司 | 放射性药物配合物 |
| WO2018153975A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| AU2018243682B2 (en) | 2017-03-30 | 2023-11-09 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| US20210187134A1 (en) | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| WO2020169538A1 (en) | 2019-02-22 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| EP4003959A1 (en) | 2019-07-25 | 2022-06-01 | Bayer AS | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| KR20230135107A (ko) | 2021-01-22 | 2023-09-22 | 바이엘 악티엔게젤샤프트 | Lrrc15 항체 및 그의 접합체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158804B2 (en) * | 2007-01-11 | 2012-04-17 | Ge Healthcare As | Chelating agents |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2015
- 2015-12-14 MA MA041176A patent/MA41176A/fr unknown
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/es unknown
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/en active Pending
- 2015-12-15 UA UAA201707516A patent/UA125369C2/uk unknown
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/es unknown
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 CR CR20170256A patent/CR20170256A/es unknown
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/en active Application Filing
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/ko not_active Application Discontinuation
- 2015-12-15 EA EA201791350A patent/EA201791350A9/ru unknown
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/pt not_active Application Discontinuation
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/zh active Active
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/ja active Active
- 2015-12-15 MX MX2017008093A patent/MX2017008093A/es unknown
- 2015-12-15 CU CU2017000082A patent/CU24493B1/es unknown
- 2015-12-15 CA CA2970841A patent/CA2970841A1/en active Pending
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/ar active
- 2015-12-17 AR ARP150104130A patent/AR103063A1/es unknown
- 2015-12-17 TW TW104142567A patent/TWI654179B/zh active
- 2015-12-17 UY UY0001036453A patent/UY36453A/es not_active Application Discontinuation
-
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/es unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/es unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/es unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/es unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/es unknown
-
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/ja active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170082A7 (es) | Complejo de torio dirigido a tejido y método para su preparación | |
| BR112018075554A2 (pt) | complexos radiofarmacêuticos | |
| PH12016500566A1 (en) | Anti-pdl1 antibody formulations | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| BR112019000026A2 (pt) | sais de ácido diorganilfosfínico, método para sua produção e seu uso | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| BR112018003331A2 (pt) | sondas para imagear proteína huntingtina | |
| EA201990093A1 (ru) | Двухкомпонентная композиция | |
| CO2018010024A2 (es) | Complejos radiofarmacéuticos | |
| BR112018069110A2 (pt) | uso de uma composição aquosa para dissolução de biomoléculas de uma amostra de tecido |